Mingcai Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mingcai Li has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Yan Li
Department of Pathogenic Biology and Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University
19 shared publications- Yan Li
School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo 315211, China
18 shared publications Xiao Peng
Ningbo Univ, Dept Immunol, Sch Med, 818 Fenghua Rd, Ningbo 315211, Peoples R China
10 shared publicationsXiuhe Pan
School of Medicine, Ningbo University, Ningbo, China
8 shared publicationsLuping Gong
Zhejiang Key Laboratory of Pathophysiology, Ningbo University Health Science Center, Ningbo 315211, China
7 shared publicationsKeye Xu
Department of Immunology, Zhejiang Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo 315211, China
6 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
The role of IL-1 family cytokines in Sjögren’s syndrome
Sjögren’s syndrome (SS) is a prevalent autoimmune disorder primarily characterized by xerostomia and keratoconjunctivitis sicca. The interleukin-1 (IL-1) cytokine family is implicated in the pathogenesis of SS during its onset and progression. Members of this cytokine family contribute to various pathological pathways in SS by facilitating the aberrant activation of salivary gland epithelial cells, augmenting type 1 immune responses, and modulating Th17 cell differentiation and function. This paper offers a comprehensive review of the historical and recent research advances in research on the mechanisms of action of IL-1 family cytokines in SS, with the objective of providing a theoretical foundation for the clinical diagnosis and management of SS.
- 27 October 2026
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
Open AccessThe role of IL-1 family cytokines in Sjögren’s syndrome
Sjögren’s syndrome (SS) is a prevalent autoimmune disorder primarily characterized by xerostomia and keratoconjunctivitis sicca. The interleukin-1 (IL-1) cytokine family is implicated in the pathogenesis of SS during its onset and progression. Members of this cytokine family contribute to various pathological pathways in SS by facilitating the aberrant activation of salivary gland epithelial cells, augmenting type 1 immune responses, and modulating Th17 cell differentiation and function. This paper offers a comprehensive review of the historical and recent research advances in research on the mechanisms of action of IL-1 family cytokines in SS, with the objective of providing a theoretical foundation for the clinical diagnosis and management of SS.
- Open Access
- 3 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Elevated serum interleukin-38 levels in polymyositis and dermatomyositis: diagnostic implications and correlations with inflammatory markers
Background: Interleukin (IL)-38 has been recently identified as an anti-inflammatory cytokine. Polymyositis (PM) and dermatomyositis (DM) are two prevalent clinical inflammatory myopathies. This study aims to investigate the serum concentrations of IL-38 in patients with PM/DM and their association with these conditions. Methods: Serum IL-38 levels were quantified using the enzyme-linked immunosorbent assay method in a cohort of 117 subjects, comprising 77 patients with myositis (8 with PM and 69 with DM) and 40 healthy controls. A comprehensive assessment of preliminary clinical characteristics was conducted for each participant through physical examination and review of medical records. The diagnostic utility of IL-38 in PM/DM was evaluated using the receiver operating characteristic curve. Results: The findings revealed that serum IL-38 concentrations were significantly elevated in patients with PM/DM compared to the control group, irrespective of the presence of interstitial lung disease. No significant difference was observed between the PM and DM groups. Furthermore, IL-38 demonstrated a positive correlation with the visual analogue scale, lactate dehydrogenase (LDH), and other inflammatory markers. Finally, IL-38, either independently or in conjunction with LDH, exhibits significant diagnostic potential. Conclusion: The study’s findings reveal that patients with PM/DM who present elevated serum levels of IL-38 also show a positive correlation with LDH levels. This suggests IL-38 may participate in modulating inflammatory immune responses in PM/DM and could serve as a potential candidate indicator for these conditions.
- 3 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Open AccessElevated serum interleukin-38 levels in polymyositis and dermatomyositis: diagnostic implications and correlations with inflammatory markers
Background: Interleukin (IL)-38 has been recently identified as an anti-inflammatory cytokine. Polymyositis (PM) and dermatomyositis (DM) are two prevalent clinical inflammatory myopathies. This study aims to investigate the serum concentrations of IL-38 in patients with PM/DM and their association with these conditions. Methods: Serum IL-38 levels were quantified using the enzyme-linked immunosorbent assay method in a cohort of 117 subjects, comprising 77 patients with myositis (8 with PM and 69 with DM) and 40 healthy controls. A comprehensive assessment of preliminary clinical characteristics was conducted for each participant through physical examination and review of medical records. The diagnostic utility of IL-38 in PM/DM was evaluated using the receiver operating characteristic curve. Results: The findings revealed that serum IL-38 concentrations were significantly elevated in patients with PM/DM compared to the control group, irrespective of the presence of interstitial lung disease. No significant difference was observed between the PM and DM groups. Furthermore, IL-38 demonstrated a positive correlation with the visual analogue scale, lactate dehydrogenase (LDH), and other inflammatory markers. Finally, IL-38, either independently or in conjunction with LDH, exhibits significant diagnostic potential. Conclusion: The study’s findings reveal that patients with PM/DM who present elevated serum levels of IL-38 also show a positive correlation with LDH levels. This suggests IL-38 may participate in modulating inflammatory immune responses in PM/DM and could serve as a potential candidate indicator for these conditions.
- Open Access
- 18 August 2025
- Published by Taylor & Francis in Future Science OA
- Vol. 11 (1) , 2545732
Elevated serum interleukin-41 levels as a potential biomarker in ankylosing spondylitis
Interleukin (IL)-41 is a novel cytokine, also known as Metrnl, and its role in ankylosing spondylitis (AS) remains unknown. The aim of this study is to measure the serum IL-41 levels in AS patients and their correlation with other clinical indicators. This study recruited 106 participants, including 32 active AS patients, 32 inactive AS patients, and 42 healthy controls (HC). Basic information and clinical indicators of participants were obtained through physical examination and blood sample testing. Enzyme-linked immunosorbent assay was used to detect IL-41 levels. Patients with active and inactive AS had significantly higher serum IL-41 levels than HC. Moreover, correlation analysis showed that IL-41 in active AS was positively correlated with lymphocyte percentage; IL-41 in inactivated AS is negatively correlated with alkaline phosphatase and creatinine. IL-41 as an independent protective factor for AS had good value for the diagnosis of AS. This study indicates that serum IL-41 levels are elevated in both active and inactive AS patients, suggesting that IL-41 may be a novel biomarker for AS.
- 18 August 2025
- Published by Taylor & Francis in Future Science OA
- Vol. 11 (1) , 2545732
Open AccessElevated serum interleukin-41 levels as a potential biomarker in ankylosing spondylitis
Interleukin (IL)-41 is a novel cytokine, also known as Metrnl, and its role in ankylosing spondylitis (AS) remains unknown. The aim of this study is to measure the serum IL-41 levels in AS patients and their correlation with other clinical indicators. This study recruited 106 participants, including 32 active AS patients, 32 inactive AS patients, and 42 healthy controls (HC). Basic information and clinical indicators of participants were obtained through physical examination and blood sample testing. Enzyme-linked immunosorbent assay was used to detect IL-41 levels. Patients with active and inactive AS had significantly higher serum IL-41 levels than HC. Moreover, correlation analysis showed that IL-41 in active AS was positively correlated with lymphocyte percentage; IL-41 in inactivated AS is negatively correlated with alkaline phosphatase and creatinine. IL-41 as an independent protective factor for AS had good value for the diagnosis of AS. This study indicates that serum IL-41 levels are elevated in both active and inactive AS patients, suggesting that IL-41 may be a novel biomarker for AS.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 4755-4770
Interleukin −39 Expression in Pleural Effusion and Its Diagnostic Value for Tuberculous Pleurisy
Objective: This study aimed to assess Interleukin-39 (IL-39) levels in various types of pleural effusion (PE), explore IL-39’s diagnostic value in tuberculous pleurisy, analyze its correlation with other PE and tuberculosis indicators, and confirm the involvement of IL-39 in tuberculosis infection and the resulting inflammatory response. Methods: This study enrolled 113 patients with PE caused by different etiologies: 20 with transudative effusion, 39 with malignant pleural effusion (MPE), 15 with uncomplicated parapneumonic effusion (UPPE), and 39 with tuberculous pleural effusion (TPE). Enzyme-linked immunosorbent assay (ELISA) was used to measure IL-39, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels in the pleural fluid (PF) of each group. Adenosine deaminase (ADA) activity was determined using the colorimetric method. Results: IL-39 concentration was notably higher in the TPE compared to others. The IL-39 demonstrated an AUC of 0.944, with a cut-off value of 39.8 pg/mL, sensitivity of 94.9%, and specificity of 79.7% in distinguishing between the TPE and non-TPE. In discriminating between the TPE and MPE, the AUC for IL-39 was 0.941, with a cut-off value of 39.3 pg/mL, sensitivity of 94.9%, and specificity of 79.5%. For differentiating the TPE and UPPE, IL-39 yielded an AUC of 0.885, with a cut-off value of 235.0 pg/mL, sensitivity of 66.7%, and specificity of 100.0%. Moreover, based on these findings, multivariable diagnostic model and the rapid combination of IL-39 with other tuberculosis biomarkers (such as IFN-γ, TNF-α, and ADA) significantly enhanced the diagnostic and differential diagnostic performance for TPE. Additionally, IL-39, IFN-γ, TNF-α, and ADA levels in PF were positively correlated with each other. Conclusion: IL-39 demonstrated good diagnostic and differential diagnostic value for TPE. Furthermore, the multivariate diagnostic model, as well as the joint detection of IL-39 with other tuberculosis biomarkers, can further increased the sensitivity or specificity. Additionally, IL-39 exhibited positive correlations with other tuberculosis biomarkers, suggesting its potential involvement in tuberculosis infection and the inflammatory response it may induce.
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 4755-4770
Open AccessInterleukin −39 Expression in Pleural Effusion and Its Diagnostic Value for Tuberculous Pleurisy
Objective: This study aimed to assess Interleukin-39 (IL-39) levels in various types of pleural effusion (PE), explore IL-39’s diagnostic value in tuberculous pleurisy, analyze its correlation with other PE and tuberculosis indicators, and confirm the involvement of IL-39 in tuberculosis infection and the resulting inflammatory response. Methods: This study enrolled 113 patients with PE caused by different etiologies: 20 with transudative effusion, 39 with malignant pleural effusion (MPE), 15 with uncomplicated parapneumonic effusion (UPPE), and 39 with tuberculous pleural effusion (TPE). Enzyme-linked immunosorbent assay (ELISA) was used to measure IL-39, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels in the pleural fluid (PF) of each group. Adenosine deaminase (ADA) activity was determined using the colorimetric method. Results: IL-39 concentration was notably higher in the TPE compared to others. The IL-39 demonstrated an AUC of 0.944, with a cut-off value of 39.8 pg/mL, sensitivity of 94.9%, and specificity of 79.7% in distinguishing between the TPE and non-TPE. In discriminating between the TPE and MPE, the AUC for IL-39 was 0.941, with a cut-off value of 39.3 pg/mL, sensitivity of 94.9%, and specificity of 79.5%. For differentiating the TPE and UPPE, IL-39 yielded an AUC of 0.885, with a cut-off value of 235.0 pg/mL, sensitivity of 66.7%, and specificity of 100.0%. Moreover, based on these findings, multivariable diagnostic model and the rapid combination of IL-39 with other tuberculosis biomarkers (such as IFN-γ, TNF-α, and ADA) significantly enhanced the diagnostic and differential diagnostic performance for TPE. Additionally, IL-39, IFN-γ, TNF-α, and ADA levels in PF were positively correlated with each other. Conclusion: IL-39 demonstrated good diagnostic and differential diagnostic value for TPE. Furthermore, the multivariate diagnostic model, as well as the joint detection of IL-39 with other tuberculosis biomarkers, can further increased the sensitivity or specificity. Additionally, IL-39 exhibited positive correlations with other tuberculosis biomarkers, suggesting its potential involvement in tuberculosis infection and the inflammatory response it may induce.
- Open Access
- 17 October 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1434738
The decreased serum levels of interleukin-38 in patients with gout and its clinical significance
Background: Interleukin (IL)-38 is a newly discovered anti-inflammatory cytokine. However, its concentration and clinical significance in patients with gout remain unclear. This study aimed to investigate the levels of IL-38 in patients with gout and evaluate their clinical significance.Methods: Thirty-two patients with active gout, 27 patients with inactive gout, and 20 negative controls (NCs) were included in the study. Clinical parameters, including white blood cell count, C-reactive protein, serum amyloid A, erythrocyte sedimentation rate, uric acid, urea, creatinine, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, and glycoserated serum protein, were obtained from laboratory tests of blood samples. The serum concentration of IL-38 was determined using enzyme-linked immunosorbent assay. Spearman’s correlation analysis and receiver operating characteristic curve assessments were used to investigate the role and diagnostic value of IL-38 in gout.Results: Patients with active and inactive gout exhibited significantly lower serum IL-38 levels than NCs. No significant differences were observed between the two gout groups. A negative correlation was observed between IL-38 and white blood cell counts, whereas a positive correlation was found between IL-38 and creatinine levels. Furthermore, IL-38, either alone or in combination with uric acid, demonstrated substantial diagnostic potential.Conclusion: The findings suggest that the decreased serum levels of IL-38 in patients with gout compared to that in NCs indicates that IL-38 may have immunomodulatory effects on gout inflammation and possesses clinical application value.
- 17 October 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1434738
Open AccessThe decreased serum levels of interleukin-38 in patients with gout and its clinical significance
Background: Interleukin (IL)-38 is a newly discovered anti-inflammatory cytokine. However, its concentration and clinical significance in patients with gout remain unclear. This study aimed to investigate the levels of IL-38 in patients with gout and evaluate their clinical significance.Methods: Thirty-two patients with active gout, 27 patients with inactive gout, and 20 negative controls (NCs) were included in the study. Clinical parameters, including white blood cell count, C-reactive protein, serum amyloid A, erythrocyte sedimentation rate, uric acid, urea, creatinine, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, and glycoserated serum protein, were obtained from laboratory tests of blood samples. The serum concentration of IL-38 was determined using enzyme-linked immunosorbent assay. Spearman’s correlation analysis and receiver operating characteristic curve assessments were used to investigate the role and diagnostic value of IL-38 in gout.Results: Patients with active and inactive gout exhibited significantly lower serum IL-38 levels than NCs. No significant differences were observed between the two gout groups. A negative correlation was observed between IL-38 and white blood cell counts, whereas a positive correlation was found between IL-38 and creatinine levels. Furthermore, IL-38, either alone or in combination with uric acid, demonstrated substantial diagnostic potential.Conclusion: The findings suggest that the decreased serum levels of IL-38 in patients with gout compared to that in NCs indicates that IL-38 may have immunomodulatory effects on gout inflammation and possesses clinical application value.
- 18 April 2024
- Published by Taylor & Francis in Immunological Investigations
- Vol. 53 (5) , 788-799
The Clinical Significance of Serum Interleukin-36α Levels in Patients with Gout
Background: Gout is a chronic inflammatory diseases caused by monosodium urate crystal deposition. However, the role of interleukin (IL)-36 in gout has not dbeen elucidated. Methods: We enrolled 75 subjects, including 20 healthy controls (HC), 30 patients with acute gout attack and 25 patients in remission. Baseline data were obtained through clinical interrogation and laboratory data were obtained through tests of blood samples. Serum levels of IL-36 alpha were detected using enzyme-linked immunosorbent assay. Spearman correlation analysis was used to investigate the correlation of IL-36 alpha with other parameters. The diagnostic value of IL-36 alpha was demonstrated using a receiver operating characteristic curve. Results: The serum IL-36 alpha level of gout patients in acute attack and remission stage was significantly higher than that of HC. Serum IL-36 alpha was positively correlated with alanine transaminase (ALT) and aspartate transaminase (AST). Serum amyloid A (SAA) levels positively correlated with C-reactive protein levels and erythrocyte sedimentation rates. Glutamyl transpeptidase levels positively correlated with AST and ALT levels. Conclusion: In conclusion, serum IL-36 alpha levels were elevated in patients with gout and correlated with the clinical markers of inflammation. Our findings suggest that IL-36 alpha may be a novel inflammatory indicator for gout.
- 18 April 2024
- Published by Taylor & Francis in Immunological Investigations
- Vol. 53 (5) , 788-799
The Clinical Significance of Serum Interleukin-36α Levels in Patients with Gout
Background: Gout is a chronic inflammatory diseases caused by monosodium urate crystal deposition. However, the role of interleukin (IL)-36 in gout has not dbeen elucidated. Methods: We enrolled 75 subjects, including 20 healthy controls (HC), 30 patients with acute gout attack and 25 patients in remission. Baseline data were obtained through clinical interrogation and laboratory data were obtained through tests of blood samples. Serum levels of IL-36 alpha were detected using enzyme-linked immunosorbent assay. Spearman correlation analysis was used to investigate the correlation of IL-36 alpha with other parameters. The diagnostic value of IL-36 alpha was demonstrated using a receiver operating characteristic curve. Results: The serum IL-36 alpha level of gout patients in acute attack and remission stage was significantly higher than that of HC. Serum IL-36 alpha was positively correlated with alanine transaminase (ALT) and aspartate transaminase (AST). Serum amyloid A (SAA) levels positively correlated with C-reactive protein levels and erythrocyte sedimentation rates. Glutamyl transpeptidase levels positively correlated with AST and ALT levels. Conclusion: In conclusion, serum IL-36 alpha levels were elevated in patients with gout and correlated with the clinical markers of inflammation. Our findings suggest that IL-36 alpha may be a novel inflammatory indicator for gout.
- 28 September 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (9) , 2381-2390
Elevated serum IL-36γ levels in patients with ankylosing spondylitis and its association with disease activity
Ankylosing spondylitis (AS) is a chronic autoimmune disease. The purpose of this study was to investigate the levels of serum IL-36γ in AS patients and their association with AS. The study enrolled 131 subjects, including 45 with active AS, 46 with inactive AS, and 40 healthy controls (HCs). The basic clinical information of each participant was obtained through physical examination and relevant clinical medical records. Serum IL-36γ levels were detected through an enzyme-linked immunosorbent assay. Serum IL-36γ levels in the active AS group were significantly higher than those in the HC group (94.72 vs. 65.76 pg/mL, P = 0.0087). The serum IL-36γ concentration in the inactive AS group was increased as compared to that in the HC group (100.90 vs. 65.76 pg/mL, P = 0.0138). Correlation analysis indicated that serum IL-36γ was positively correlated with glutamyl transferase in the active AS group (P = 0.0172), while serum IL-36γ was positively correlated with uric acid in the inactive AS group (P = 0.0151). The area under the curve (AUC) for IL-36γ was 0.6824 (P = 0.0009), and the AUC for IL-36γ combined with the erythrocyte sedimentation rate and C-reactive protein levels was 0.8102 (P < 0.0001), according to receiver operating characteristic curve analysis. This study found that serum IL-36γ levels were elevated in AS patients and correlated with disease activity. Our results suggest that IL-36γ may be involved in the progression of AS disease and is a potential biomarker for AS.
- 28 September 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (9) , 2381-2390
Elevated serum IL-36γ levels in patients with ankylosing spondylitis and its association with disease activity
Ankylosing spondylitis (AS) is a chronic autoimmune disease. The purpose of this study was to investigate the levels of serum IL-36γ in AS patients and their association with AS. The study enrolled 131 subjects, including 45 with active AS, 46 with inactive AS, and 40 healthy controls (HCs). The basic clinical information of each participant was obtained through physical examination and relevant clinical medical records. Serum IL-36γ levels were detected through an enzyme-linked immunosorbent assay. Serum IL-36γ levels in the active AS group were significantly higher than those in the HC group (94.72 vs. 65.76 pg/mL, P = 0.0087). The serum IL-36γ concentration in the inactive AS group was increased as compared to that in the HC group (100.90 vs. 65.76 pg/mL, P = 0.0138). Correlation analysis indicated that serum IL-36γ was positively correlated with glutamyl transferase in the active AS group (P = 0.0172), while serum IL-36γ was positively correlated with uric acid in the inactive AS group (P = 0.0151). The area under the curve (AUC) for IL-36γ was 0.6824 (P = 0.0009), and the AUC for IL-36γ combined with the erythrocyte sedimentation rate and C-reactive protein levels was 0.8102 (P < 0.0001), according to receiver operating characteristic curve analysis. This study found that serum IL-36γ levels were elevated in AS patients and correlated with disease activity. Our results suggest that IL-36γ may be involved in the progression of AS disease and is a potential biomarker for AS.
- 21 August 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 124 (Pt A) , 110794
Interleukin-41 diminishes cigarette smoke-induced lung inflammation in mice
- 21 August 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 124 (Pt A) , 110794
Interleukin-41 diminishes cigarette smoke-induced lung inflammation in mice